Regulation of mouse mammary tumor virus env transcriptional activator initiated mammary tumor virus superantigen transcripts in lymphomas of SJL/J mice: role of Ikaros, demethylation, and chromatin structural change in the transcriptional activation of mammary tumor virus superantigen.
Mammary tumor virus (Mtv29)-encoded superantigen expressed by SJL/J mouse B cell lymphomas stimulates CD4+V16+ T cells and thereby acquires T cell help necessary for lymphoma growth. Mtv29 mouse mammary tumor virus env transcriptional activator (META) env-controlled Mtv29 superantigen (vSAg29) mRNA transcripts (1.8 kb) are not expressed in normal B or other somatic cells. Real-time PCR-based assays with DNA from normal SJL liver and vSAg29- lymphoma (cNJ101), digested with methylation-sensitive enzymes, showed hypermethylation at AvaI, FspI, HpaII, ThaI, and the distal HgaI sites of the META env, but vSAg29+ lymphoma cells showed significant demethylation at AvaI, HpaII, and the distal HgaI sites. The distal HgaI site that is adjacent to an Ikaros binding site is significantly demethylated in the META env DNA from primary lymphomas. Gel shift assays showed binding of Ikaros to a sequence representing this region in the META env. SJL lymphomas expressed the Ikaros isoform Ik6 that was absent in normal B cells. vSAg29+ cells exhibited increased DNaseI accessibility to chromatin at the vSAg29 initiation site. Treatment of cNJ101 cells with a demethylating agent, 5-azacytidine, and a histone deacetylase inhibitor, trichostatin A, caused hypomethylation at AvaI, HpaII, and distal HgaI sites and led to chromatin structural change at the vSAg29 initiation site, accompanied by the expression of vSAg29 transcripts. This enabled cNJ101 cells to stimulate SJL lymphoma-responsive CD4+V16+ T hybridoma cells. Thus, demethylation at the distal HgaI site of the Mtv29 META env permits vSAg29 expression, which may have an impact on the development of germinal center-derived B cell lymphomas of SJL/J mice.
Thomas
Rajan M
RM
Department of Pathology and Comprehensive Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Haleem
Kamran
K
Siddique
Abu B
AB
Simmons
William J
WJ
Sen
Namita
N
Zhang
Da-Jun
DJ
Tsiagbe
Vincent K
VK
D000818:Animals; D001374:Azacitidine / Q000494:pharmacology; D002843:Chromatin / Q000737:chemistry* / Q000201:enzymology / Q000378:metabolism; D019175:DNA Methylation; D004268:DNA-Binding Proteins; D003850:Deoxyribonuclease I / Q000378:metabolism; D005260:Female; D015752:Genes, env / Q000502:physiology*; D006877:Hydroxamic Acids / Q000494:pharmacology; D051740:Ikaros Transcription Factor; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000276:immunology* / Q000821:virology; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics / Q000276:immunology*; D051379:Mice; D011401:Promoter Regions, Genetic / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis; D012192:Retroviridae Infections / Q000235:genetics / Q000276:immunology; D018089:Superantigens / Q000235:genetics* / Q000378:metabolism; D015534:Trans-Activators / Q000378:metabolism / Q000502:physiology*; D014157:Transcription Factors / Q000502:physiology*; D014158:Transcription, Genetic / Q000276:immunology*; D015533:Transcriptional Activation / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000235:genetics / Q000276:immunology
D002843:Chromatin; D004268:DNA-Binding Proteins; D006877:Hydroxamic Acids; D012333:RNA, Messenger; D018089:Superantigens; D015534:Trans-Activators; D014157:Transcription Factors; C497238:Zfpn1a1 protein, mouse; D051740:Ikaros Transcription Factor; C012589:trichostatin A; D003850:Deoxyribonuclease I; D001374:Azacitidine